A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512115-50-00

Acronym

KCP-330-009

Enrollment

Registered

2024-06-24

Start date

2016-06-22

Completion date

Unknown

Last updated

2025-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/Refractory DLBCL

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Greece, Italy, Poland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026